Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review

Journal of Human Hypertension volume 23, pages 495–502 (2009)Cite this article

Abstract

We conducted a systematic review and meta-analysis of double-blind randomized controlled trials to quantify the dose-related systolic (SBP) and diastolic blood pressure (DBP) lowering efficacy of renin inhibitors vs placebo in the treatment of adults with primary hypertension. Databases searched were Medline (1966–March 2008), EMBASE (1988–March 2008) and Cochrane Central Register of Controlled Trials (CENTRAL). Six trials in 3694 patients met the inclusion criteria. All examined aliskiren, the only renin inhibitor licensed for marketing in Canada and the United States. Aliskiren caused a dose-related SBP/DBP lowering effect compared to placebo: weighted mean difference with 95% CI: aliskiren 75 mg, −2.9 (−4.6, −1.3)/−2.3 (−3.3, −1.3) mm Hg; aliskiren 150 mg, −5.5 (−6.5, −4.4)/−3.0 (−3.7, −2.3) mm Hg; aliskiren 300 mg, −8.7 (−9.7,−7.6)/−5.0 (−5.6, −4.3) and aliskiren 600 mg, −11.4 (−13.5, −9.2)/−6.6 (−7.9, −5.2) mm Hg. Aliskiren 300 mg significantly lowered both SBP −3.0 (−4.0, −2.0) and DBP −1.7 (−2.3, −1.0) as compared to aliskiren150 mg. Aliskiren has no effect on blood pressure variability. No data were available to assess the effect of aliskiren on heart rate or pulse pressure. This review found weak evidence that during 4- to 8-week use, aliskiren did not increase withdrawals due to adverse effects as compared to placebo. We concluded that aliskiren has a dose-related blood pressure lowering effect better than placebo and magnitude of effect is similar to that determined for angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Helmer OM . Studies on renin antibodies. Circulation 1958; 17: 648–652.

    Article  CAS  Google Scholar 

  2. Frishman WH, Fozailoff A, Lin C, Dike C . Renin inhibition: a new approach to cardiovascular therapy. J Clin Pharmacol 1994; 34: 873–880.

    Article  CAS  Google Scholar 

  3. Krum H, Gilbert RE . Novel therapies blocking the renin–angiotensin–aldosterone system in the management of hypertension and related disorders. J Hypertens 2007; 25: 25–35.

    Article  CAS  Google Scholar 

  4. Kushiro T, Hiroshige I, Yoshihisa A, Hiromi G, Shinji T, Keefe D . Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29: 997–1005.

    Article  CAS  Google Scholar 

  5. Pool J, Roland E, Schmieder M, Aldigier JC, Januszewicz A, Zidek W et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11–20.

    Article  CAS  Google Scholar 

  6. Villamil A, Chrysant S, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217–226.

    Article  CAS  Google Scholar 

  7. Oparil S, Yarrows S, Patel S, Fang H, Zhang J, Satlin A . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221–229.

    Article  CAS  Google Scholar 

  8. Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M . Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012–1018.

    Article  CAS  Google Scholar 

  9. Oh B, Mitchell J, Herron J, Chung J, Khan ML, Keefe D . Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157–1163.

    Article  CAS  Google Scholar 

  10. Duprez D . Role of the renin–angiotensin–aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006; 24: 983–991.

    Article  CAS  Google Scholar 

  11. Heran BS, Wong MMY, Heran IK, Wright JM . Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database of Syst Rev 2008; Issue 4. Art. No.: CD003823. doi:10.1002/14651858.CD003823.pub2.

  12. Heran BS, Wong MMY, Heran IK, Wright JM . Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database of Syst Rev 2008; Issue 4. Art. No.: CD003822. doi:10.1002/14651858.CD003822.pub2.

  13. Law MR, Wald NJ, Morris JK, Jordan RE . Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the Cochrane Hypertension Review Group for publishing this review in the Cochrane database of systematic review issue 4, 2008. We also acknowledge the contribution of Stephen Adams and Ciprian Jauca who assisted in editing of this review. We also thank the Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Canada, and Canadian Institutes of Health Research, Canada, for providing financial support.

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Pharmacology and Therapeutics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

    V M Musini, P M Fortin, K Bassett & J M Wright

Authors
  1. V M Musini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P M Fortin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Bassett
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J M Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V M Musini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Musini, V., Fortin, P., Bassett, K. et al. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review. J Hum Hypertens 23, 495–502 (2009). https://doi.org/10.1038/jhh.2008.162

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2008.162

Keywords

This article is cited by

Search

Advanced search

Quick links